Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To determine the efficacy of (90)Y [DOTA(0), D-Phe(1), Tyr(3)]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Future Oncol

Title: Future oncology (London, England)

Publisher: Future Medicine Ltd

ISSN (Electronic): 1744-8301

ISSN (Print): 1479-6694

Publication date (Electronic): Aug 2016

Volume: 12

Issue: 16

Affiliations

[1 ] Clinical Department of Chemotherapy, Hospital Ministry of the Interior & Administration & Warmia & Mazury Oncology Centre, Olsztyn, Poland.

[2 ] Department of Endocrinology, Medical University of Gdansk, Gdansk, Poland.

[3 ] Department of Nuclear Medicine & PET, Addenbrooke's Hospital, Cambridge, UK.

[4 ] Department of Radiology & Diagnostic Imaging, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.

[5 ] Faculty of Medical Science, University of Varmia & Masuria, Olsztyn, Poland.

Article

DOI: 10.2217/fon-2016-0031

PubMed ID: 27156864

SO-VID: ce8cce90-2ae2-4d06-ae38-9909e023dfb5

History

Keywords: 90Y-DOTATATE therapy,GEP-NET,clinical and radiological response

Data availability:

Keywords: 90Y-DOTATATE therapy, GEP-NET, clinical and radiological response

Comments

Comment on this article

scite_

Cited by 4

See all cited by